Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Man triggers smoke bomb during failed crypto robbery - 2Instructions to Pick the Right Dental Expert for Teeth Substitution
- 3More parents refusing this shot that prevents serious bleeding at birth
- 4Geminid shooting stars: One of 2025's most exciting meteor showers begins tonight
- 5Miley Cyrus flashes a diamond ring on the red carpet, sparking engagement rumors with Maxx Morando: A timeline of their four-year relationship
- Polar bears are rewiring their own genetics to survive a warming climate
- Violence 'never part' of break-in plan, court told
- A Pompeii site reveals the recipe for Roman concrete. It contradicts a famous architect’s writings
- Manual for Savvy Home Lighting Framework: Lights up Your Space
- Storm Goretti sweeps United Kingdom, France with winds over 120 mph
- Israel violated ceasefire with Hezbollah more than 10,000 times, UNIFIL claims
- Most loved VR Game for Wellness: Which Keeps You Dynamic?
- The most effective method to Pick the Ideal Lab Precious stone Wedding band
- Manual for Purchasing a Modest Jeep Wrangler for Seniors
